<?xml version="1.0" encoding="UTF-8"?>
<feed xmlns="http://www.w3.org/2005/Atom" xmlns:dc="http://purl.org/dc/elements/1.1/">
  <title>DSpace Collection: Materialele Congresului V Naţional de Dermatologie cu participare internaţională Chişinău, 9-11 iunie 2016, Chişinău, Republica Moldova</title>
  <link rel="alternate" href="http://repository.usmf.md:80/handle/20.500.12710/1131" />
  <subtitle>Materialele Congresului V Naţional de Dermatologie cu participare internaţională Chişinău, 9-11 iunie 2016, Chişinău, Republica Moldova</subtitle>
  <id>http://repository.usmf.md:80/handle/20.500.12710/1131</id>
  <updated>2026-04-23T11:50:35Z</updated>
  <dc:date>2026-04-23T11:50:35Z</dc:date>
  <entry>
    <title>Curierul medical. Iunie 2016, Vol. 59, No 3</title>
    <link rel="alternate" href="http://repository.usmf.md:80/handle/20.500.12710/16196" />
    <author>
      <name />
    </author>
    <id>http://repository.usmf.md:80/handle/20.500.12710/16196</id>
    <updated>2021-09-22T13:14:38Z</updated>
    <published>2016-01-01T00:00:00Z</published>
    <summary type="text">Title: Curierul medical. Iunie 2016, Vol. 59, No 3
Abstract: From its debut in 1958, the journal has striven to support the interests of&#xD;
Moldovan medicine concerning the new concepts of its development. The&#xD;
Editorial Board warmly welcomes both the readers of and the authors for the&#xD;
journal, all those who are enthusiastic in searching the new and more effective&#xD;
ways of solving numerous medical problems. We hope that those who want&#xD;
to make their contribution into the science of medicine will find our journal&#xD;
helpful and encouraging.&#xD;
The journal is accredited by the National Council for Accreditation and&#xD;
Attestation. The journal publishes official papers, scientific articles, editorials,&#xD;
clinical studies and cases, lectures, methodological guides, reviews, brief reports, and correspondence. The journal welcomes articles in English, Romanian and&#xD;
Russian. The journal editorial policy provides the prompt publication of papers&#xD;
within 12 weeks after receiving them.; De la prima apariţie în 1958, revista susţine şi dezvoltă noile idei în&#xD;
domeniul medicinii, în Republica Moldova. Colegiul de redacţie agrează cu&#xD;
multă consideraţie atât cititorii cât şi autorii articolelor, pe toţi acei care cu mult&#xD;
entuziasm caută noi şi mult mai efective metode de soluţionare a multiplelor&#xD;
probleme ale medicinii. Sperăm, că toţi acei care doresc să-şi aducă aportul&#xD;
la dezvoltarea ştiinţelor medicale, vor găsi revista noastră utilă şi atractivă.&#xD;
Revista este acreditată de către Consiliul Naţional de Acreditare și Atestare.&#xD;
Revista publică comunicări oficiale și, totodată, sunt editate diverse publicaţii,&#xD;
inclusiv independente: articole știinţifice, editoriale, cercetări și prezentări de&#xD;
cazuri clinice, prelegeri, îndrumări metodice, articole de sinteză, relatări scurte,&#xD;
corespondenţe și recenzii. Revista publică articole în limba engleză, română și&#xD;
rusă. Politica de editare a revistei prevede examinarea operativă și publicarea&#xD;
articolelor timp de 12 săptămâni după înaintare.; С первого дня своего выпуска в 1958 году журнал стремится поддерживать и развивать новые идеи в области медицины в Молдове. Редакционная коллегия всегда рада как читателям, так и авторам статей,&#xD;
всем тем, кто с энтузиазмом ищет новые, более эффективные способы&#xD;
решения многочисленных задач медицины. Мы надеемся, что все те, кто&#xD;
хотят внести свой вклад в медицинскую науку, найдут наш журнал полезным и вдохновляющим.&#xD;
Журнал аккредитован Высшей Аттестационной Комиссией Республики Молдова. В журнале печатаются официальные материалы, научные статьи, наблюдения из клинической практики, обобщающие статьи,&#xD;
краткие сообщения, методические указания, рецензии и корреспонденция. В журнале публикуются статьи на английском, румынском и русском языках. Издательская политика журнала предусматривает оперативное рассмотрение и публикацию статей в среднем в течение 12 недель после поступления.
Description: Fondatori: Ministerul Sănătăţii al Republicii Moldova, Universitatea de Stat de Medicină şi Farmacie “Nicolae Testemiţanu”.&#xD;
&#xD;
Materialele Congresului V Naţional de Dermatologie cu participare internaţională Chişinău, 9-11 iunie 2016, Chişinău, Republica Moldova</summary>
    <dc:date>2016-01-01T00:00:00Z</dc:date>
  </entry>
  <entry>
    <title>Technologies for in vitro cultivation of skin fibroblasts for patients with chronic ulcers treatment</title>
    <link rel="alternate" href="http://repository.usmf.md:80/handle/20.500.12710/15320" />
    <author>
      <name>Malcova, Tatiana</name>
    </author>
    <author>
      <name>Cirimpei, Diana</name>
    </author>
    <author>
      <name>Cirimpei, Octavian</name>
    </author>
    <author>
      <name>Nacu, Viorel</name>
    </author>
    <id>http://repository.usmf.md:80/handle/20.500.12710/15320</id>
    <updated>2021-10-18T09:09:08Z</updated>
    <published>2016-01-01T00:00:00Z</published>
    <summary type="text">Title: Technologies for in vitro cultivation of skin fibroblasts for patients with chronic ulcers treatment
Authors: Malcova, Tatiana; Cirimpei, Diana; Cirimpei, Octavian; Nacu, Viorel
Abstract: Background: As many factors lead to chronic lower leg ulceration, an interdisciplinary approach to the systematic assessment of the patient is required,&#xD;
in order to ascertain the pathogenesis, definitive diagnosis, and optimal treatment.  A number of researchers propose to use in ulcers treatment non&#xD;
senescent fibroblasts. By donating additional cells to the wound environment releasing extra growth factors and reversing the antiproliferative activity&#xD;
of chronic wound exudates can be achieved.&#xD;
Material and methods: The main stages of fibroblasts’ cultivation are: obtaining of skin biopsy, donors’ serologic control, preparing culture flasks,&#xD;
separation of epidermis and dermis, proper cultivation, cells bacteriological control and application.&#xD;
Results: The final cell density in primary culture was 4,5*104 cells/cm2&#xD;
. It’s demonstrated that tissue-engineered human dermal fibroblasts can replace&#xD;
the dermis and provide essential stimulatory growth factors for wound healing.&#xD;
Conclusions: The overall safety and lack of rejection reactions combined with the efficacy encourage the use of HFDD in addition to good wound&#xD;
care practices</summary>
    <dc:date>2016-01-01T00:00:00Z</dc:date>
  </entry>
  <entry>
    <title>Skinboosters – rolul acidului hialuronic în tratamentul cicatricilor postacneice</title>
    <link rel="alternate" href="http://repository.usmf.md:80/handle/20.500.12710/13386" />
    <author>
      <name>Şoşoacă, Ina</name>
    </author>
    <id>http://repository.usmf.md:80/handle/20.500.12710/13386</id>
    <updated>2021-10-18T09:15:12Z</updated>
    <published>2016-01-01T00:00:00Z</published>
    <summary type="text">Title: Skinboosters – rolul acidului hialuronic în tratamentul cicatricilor postacneice
Authors: Şoşoacă, Ina
Abstract: În societatea modernă, aspectul fizic joacă un rol extrem de important, atât în viaţa personală, cât şi în cea profesională a&#xD;
fiecărui individ. Unul din factorii care influenţează în mod negativ demersul echilibrat al evenimentelor, trăirilor sau experienţelor&#xD;
din viaţa noastră, este exprimat de prezenţa cicatricilor postacneice la nivelul chipului, acestea afectând semnificativ calitatea&#xD;
vieţii pacienţilor.&#xD;
Alegerea metodei de tratament a cicatricilor postacneice se face în funcţie de tipul şi forma acestora, gradul de severitate şi&#xD;
culoare, mărimea şi localizarea, dar şi experienţa, tratamentele anterioare, prezenţa sau absenţa inflamaţiei.&#xD;
În ceea ce priveşte tratamentul cicatricilor, un mare succes îl are gama Restylane Skinboosters – fillere dermice cu acid&#xD;
hialuronic. Acidul hialuronic creşte conţinutul de apă în spaţiul extracelular, reface mediul fiziologic în derm, optimizează&#xD;
enzimele şi stimulează metabolismul, dar şi activitatea fibroblaştilor. Are numeroase funcţii, de la redarea elasticităţii pielii&#xD;
până la lubrifierea articulaţiilor.</summary>
    <dc:date>2016-01-01T00:00:00Z</dc:date>
  </entry>
  <entry>
    <title>Alogrefele în tumorile osoase benigne</title>
    <link rel="alternate" href="http://repository.usmf.md:80/handle/20.500.12710/13385" />
    <author>
      <name>Groza, Costina</name>
    </author>
    <author>
      <name>Dascaliuc, Ion</name>
    </author>
    <author>
      <name>Topor, Boris</name>
    </author>
    <id>http://repository.usmf.md:80/handle/20.500.12710/13385</id>
    <updated>2021-10-18T09:12:58Z</updated>
    <published>2016-01-01T00:00:00Z</published>
    <summary type="text">Title: Alogrefele în tumorile osoase benigne
Authors: Groza, Costina; Dascaliuc, Ion; Topor, Boris
Abstract: Background: Bone morphogenetic proteins (BMPs) are essential mediators of bone formation involved in the regulation of differentiation of&#xD;
osteoprogenitor cells into osteoblasts. By their osteoinductive capacities, BMPs have been considered as the most potent growth factors that can promote&#xD;
the bone regeneration and repair, representing an important alternative to bone autotransplant.&#xD;
Material and methods: Underlying work is accumulated material within the Department of General Oncology and Rehabilitation Oncology Institute&#xD;
of Moldova. There were supervised 572 patients with benign tumors in the period from 2005 to 2015.&#xD;
Results: Tests revealed that the most frequent benign tumors are cartilaginous ones: osteocondroms 39 to 2.0 %, condroms 14 to 1.5%, condroblastoms&#xD;
– 2 to 0.6%. After cartilaginous tumors, second place is occupied by osteoclastoma. Rarely, patients with bone cyst and osteodisplastic fibrous bone&#xD;
lipoma are uncounted. Other processes are rarely encountered. Benign tumors more often prevail at men (58 ± 2%).&#xD;
Conclusions: Experimental and clinical studies suggested a great potential of BMPs in bone formation, especially in critical size bone defects. We&#xD;
may expect that the transplant for bone defects recovery that would satisfy the requirements of oncology can be developed.</summary>
    <dc:date>2016-01-01T00:00:00Z</dc:date>
  </entry>
</feed>

